. 2016 Sep 1;7(1):126. doi: 10.1186/s13287-016-0386-0

Table 3.

Active injury score, regeneration score, and chronicity score in OSOM of different experimental groups (n = 20 and n = 5 for days subgroups, mean ± SD)

	Group I	Group II	Group III	Group IV	Group V	Group VI
	negative control	cisplatin ‘CDDP’-treated	cisplatin + rBMSCs-treated	cisplatin + hADSCs-treated (n = 20)	cisplatin + hAFSCs-treated	cisplatin + DMEM culture media-treated
Active injury
Day 4	0.0 (0.0–0.0)	7.0 (7.0–7.0)^a	3.0 (2.0–3.0)^ab	3.0 (2.0–3.0)^ab	3.0 (2.0–3.0)^ab	6.0 (6.0–7.0)^abcde
Day 7	0.0 (0.0–0.0)	6.0 (6.0–6.0)^a	3.0 (3.0–3.0)^ab	3.0 (2.0–3.0)^ab	3.0 (2.0–3.0)^ab	6.0 (6.0–6.0)^abcde
Day 11	0.0 (0.0–0.0)	4.0 (4.0–4.0)^a	1.0 (1.0–1.0)^ab	1.0 (1.0–1.0)^ab	1.0 (1.0–1.0)^ab	6.0 (5.0–6.0)^abcde
Day 30	0.0 (0.0–0.0)	4.0 (4.0–4.0)^a	1.0 (0.0–1.0)^b	1.0 (1.0–1.0)^b	1.0 (1.0–1.0)^ab	3.0 (3.0–3.0)^abcde
Regeneration
Day 4	0.0 (0.0–0.0)	0.0 (0.0–0.0)	4.0 (4.0–5.0)^ab	4.0 (4.0–5.0)^ab	4.0 (3.0–5.0)^ab	0.0 (0.0–0.0)^cde
Day 7	0.0 (0.0–0.0)	0.0 (0.0–0.0)	6.0 (5.0–6.0)^ab	6.0 (6.0–6.0)^ab	7.0 (6.0–7.0)^abc	0.0 (0.0–0.0)^cde
Day 11	0.0 (0.0–0.0)	1.0 (1.0–2.0)^a	8.0 (7.0–8.0)^ab	8.0 (7.0–9.0)^ab	8.0 (8.0–8.0)^ab	1.0 (1.0–2.0)^acde
Day 30	0.0 (0.0–0.0)	3.0 (3.0–3.0)^a	9.0 (8.0–9.0)^ab	8.0 (7.0–9.0)^ab	8.0 (7.0–9.0)^ab	3.0 (3.0–3.0)^acde
Chronicity
Day 4	0.0 (0.0–0.0)	3.0 (3.0–3.0)^a	2.0 (1.0–2.0)^ab	2.0 (1.0–2.0)^ab	2.0 (2.0–2.0)^ab	3.0 (3.0–3.0)^acde
Day 7	0.0 (0.0–0.0)	4.0 (4.0–4.0)^a	2.0 (2.0–3.0)^ab	2.0 (2.0–2.0)^ab	2.0 (2.0–2.0)^ab	4.0 (4.0–5.0)^acde
Day 11	0.0 (0.0–0.0)	5.0 (5.0–5.0)^a	2.0 (2.0–2.0)^ab	2.0 (2.0–2.0)^ab	2.0 (2.0–2.0)^ab	5.0 (5.0–5.0)^acde
Day 30	0.0 (0.0–0.0)	3.0 (3.0–4.0)^a	2.0 (2.0–2.0)^ab	2.0 (2.0–2.0)^ab	2.0 (2.0–2.0)^ab	3.0 (3.0–3.0)^acde

Values are expressed as mean ± SD. A significant difference (P < 0.05) between different groups was done by Kruskal-Wallis test

OSOM outer strip of outer medulla, rBMSCs rat bone marrow stem cells, hADSCs human adipose tissue-derived stem cells, hAFSCs human amniotic fluid-derived stem cells, DMEM Dulbecco’s modified Eagle’s medium

^aSignificant difference vs. negative control group ^bSignificant difference vs. cisplatin-treated group ^cSignificant difference vs. cisplatin + rBMSCs-treated group ^dSignificant difference vs. cisplatin + hADSCs-treated group ^eSignificant difference vs. cisplatin + hAFSCs-treated group